1. Prevalence of Cefixime-Resistant Neisseria gonorrhoeae in Melbourne, Australia, 2021-2022.
- Author
-
Chow EPF, Stevens K, De Petra V, Chen MY, Bradshaw CS, Sherry NL, Barbee LA, Vodstrcil LA, Aguirre I, Seib KL, Maddaford K, Williamson DA, Howden BP, and Fairley CK
- Subjects
- Humans, Male, Female, Prevalence, Australia epidemiology, Adult, Microbial Sensitivity Tests, Ceftriaxone pharmacology, Ceftriaxone therapeutic use, Young Adult, Drug Resistance, Bacterial, Adolescent, Azithromycin pharmacology, Azithromycin therapeutic use, Neisseria gonorrhoeae drug effects, Cefixime pharmacology, Cefixime therapeutic use, Gonorrhea epidemiology, Gonorrhea microbiology, Gonorrhea drug therapy, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use
- Abstract
While ceftriaxone remains the first-line treatment for gonorrhea, the US Centers for Disease Control and Prevention recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021 and 2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin resistance was 4.9% (58/1176), and ceftriaxone resistance was 0% (0/1176). Cefixime resistance was highest among women (16.4%, 10/61), followed by men who have sex with women (6.4%, 7/109) and men who have sex with men (5.8%, 57/982). The prevalence of cefixime-resistant N gonorrhoeae exceeds the threshold of the 5% resistance level recommended by the World Health Organization; thus, cefixime treatment would have limited benefits in Australia., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2024
- Full Text
- View/download PDF